ALTERNATIVE VIEWS

Walter A. Brown's Opinion piece, "Alternative Medicine: It's Time to Get Smart," (The Scientist, 12[24]:13, Dec. 7, 1998) is timely and balanced. It is wishful thinking to argue that no placebo-controlled clinical studies are needed because herbs and the like have been used for hundreds of years. Those of us who have worked in pharmaceutical R&D for decades have seen too many compounds that were sworn efficacious by both physicians and patients, but could not be shown superior to a placebo.

Written byCharles Smith
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Walter A. Brown's Opinion piece, "Alternative Medicine: It's Time to Get Smart," (The Scientist, 12[24]:13, Dec. 7, 1998) is timely and balanced. It is wishful thinking to argue that no placebo-controlled clinical studies are needed because herbs and the like have been used for hundreds of years. Those of us who have worked in pharmaceutical R&D for decades have seen too many compounds that were sworn efficacious by both physicians and patients, but could not be shown superior to a placebo. All claims made by the purveyors of "alternative" medicines should have to be proven in controlled studies.

A second area that should be seriously addressed is safety. If nobody carefully follows up on the use of a medication in the population, side effects will not likely be detected unless they are serious and have high incidence. Plant products, if they are active, owe their efficacy to plant chemicals that ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies